In addition, enzalutamide treatment or AR knockdown was shown to inhibit the growth of gemcitabine-resistant bladder cancer cells, while whether it could increase chemosensitivity was not tested [89]. The gene discussed is AR; the disease is urinary bladder carcinoma.